Group 1 - The company is currently in the process of negotiating external licensing for its innovative lipid-lowering drug, specifically the LP(a) mechanism [2] - The company is committed to advancing the licensing work and will provide updates through relevant announcements as progress is made [2]

Core Viewpoint - The company is currently in the clinical I phase for its LP(a) lowering drug, and the external licensing work is progressing, with updates to be provided through official announcements [1] Group 1 - An investor inquired about the progress of the company's LP(a) lowering drug BD business, expressing concerns about the perceived slow efficiency [1] - The company confirmed that the LP(a) lowering drug is in the clinical I phase and that the external licensing efforts are ongoing [1]

Group 1 - The company currently has several innovative drugs in clinical trials, including JX11502 capsules, rehabilitation new enteric-coated capsules, and LP(a) mechanism lipid-lowering drugs [2] - The company has expressed interest in overseas business development for some of its innovative drugs [2] - The company assures that its pipeline for innovative drug development is robust and sufficient for future growth [2]